{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:56:07Z","timestamp":1780624567552,"version":"3.54.1"},"reference-count":69,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.1080\/14737175.2024.2313548","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T15:11:19Z","timestamp":1707145879000},"page":"235-249","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-7933","authenticated-orcid":false,"given":"Frank M. C.","family":"Besag","sequence":"first","affiliation":[{"name":"Child and Adolescent Mental Health Services (CAMHS), East London NHS Foundation Trust, Bedford, UK"},{"name":"School of Pharmacy, University College London, London, UK"},{"name":"Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-3531","authenticated-orcid":false,"given":"Michael J.","family":"Vasey","sequence":"additional","affiliation":[{"name":"Child and Adolescent Mental Health Services (CAMHS), East London NHS Foundation Trust, Bedford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7256-3027","authenticated-orcid":false,"given":"Richard F. M.","family":"Chin","sequence":"additional","affiliation":[{"name":"Muir Maxwell Epilepsy Centre, The University of Edinburgh, Edinburgh, UK"},{"name":"Department of Paediatric Neurosciences, Royal Hospital for Children and Young People, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3188-y"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03177.x"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00505"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70292-8"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107612"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073809348355"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14569"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003277.pub4"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2215924"},{"key":"e_1_3_4_12_1","unstructured":"National Institute for Health and Care Excellence (NICE). Epilepsies in children young people and adults. NICE Guideline [NG217] 2022 [cited 2023 Nov 28]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng217"},{"key":"e_1_3_4_13_1","unstructured":"Medicines and Healthcare products Regulatory Authority (MHRA). Valproate: reminder of current Pregnancy Prevention Programme requirements; information on new safety measures to be introduced in th coming months 2022 [updated 2022 Dec 12; cited 2023 Oct 30]. Available from: https:\/\/www.gov.uk\/drug-safety-update\/valproate-reminder-of-current-pregnancy-prevention-programme-requirements-information-on-new-safety-measures-to-be-introduced-in-the-coming-months"},{"key":"e_1_3_4_14_1","unstructured":"British national formulary (BNF) online. Treatment summaries: epilepsy [cited 2023 Nov 28]. Available from: https:\/\/bnf.nice.org.uk\/treatment-summaries\/epilepsy\/"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.08.021"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00784-8"},{"key":"#cr-split#-e_1_3_4_17_1.1","unstructured":"European Medicines Agency (EMA). Orphan designation for the treatment of Dravet syndrome 2013 [updated 2023 Apr 25"},{"key":"#cr-split#-e_1_3_4_17_1.2","unstructured":"cited 2023 Oct 20]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-13-1219"},{"key":"#cr-split#-e_1_3_4_18_1.1","unstructured":"European Medicines Agency (EMA). Orphan designation for the treatment of Lennox-Gastaut syndrome 2017. [updated 2023 Apr 25"},{"key":"#cr-split#-e_1_3_4_18_1.2","unstructured":"cited 2023 Oct 20]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-17-1836"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14540"},{"key":"e_1_3_4_20_1","unstructured":"US Food and Drug Administration (FDA). FDA approves new therapy for Dravet syndrome 2020 [cited 2023 Oct 20]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-dravet-syndrome"},{"key":"e_1_3_4_21_1","unstructured":"US Food and Drug Administration (FDA). New drug therapy approvals 2022 [cited 2023 Oct 20]. Available from: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/new-drug-therapy-approvals-2022"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801020"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00191"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.02.1072"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106989"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25169"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-030-82790-8_13","volume-title":"Fenfluramine. Antiseizure medication interactions: a clinical guide","author":"Patsalos PN","year":"2022","unstructured":"Patsalos PN. Fenfluramine. Antiseizure medication interactions: a clinical guide. Cham: Springer International Publishing; 2022. p. 81\u201384."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00755-z"},{"key":"e_1_3_4_29_1","unstructured":"UCB Pharma. FINTEPLA (fenfluramine) oral solution prescribing information 2023 [cited 2023 Oct 19]. Available from: https:\/\/www.ucb.com\/sites\/default\/files\/2023-09\/Fintepla_Current_COL_15_Sept_2023.pdf"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/children9081159"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S417676"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.5414\/cp203276"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17162"},{"key":"e_1_3_4_34_1","volume-title":"73rd American Epilepsy Society Annual Meeting","author":"Boyd B","year":"2019","unstructured":"Boyd B, Smith S, Farfel GM, et al., editors. A phase 1, single-dose, open-label pharmacokinetic study to investigate the drug-drug interaction potential of ZX008 (Fenfluramine HCl oral solution) and Cannabidiol. 73rd American Epilepsy Society Annual Meeting; Baltimore, Maryland, US. 2019 Dec."},{"key":"e_1_3_4_35_1","unstructured":"Electronic Medicines Compendium (emc). Fintepla 2.2 mg\/mL oral solution. Summary Of Product Characteristics (SmPC) 2023 [updated 09 Oct 2023; cited 01 Dec 2023]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/11998\/smpc#gref"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32500-0"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0829"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17431"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.04.004"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15072"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2012.09.039"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.01.037"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.01.002"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01334.x"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17000"},{"key":"e_1_3_4_46_1","first-page":"125","volume-title":"Epileptic syndromes in infancy, childhood and adolescence","author":"Beaumanoir A","year":"2005","unstructured":"Beaumanoir A, Blume W. The Lennox-Gastaut syndrome. In: Roger J, Bureau M Dravet C, editors Epileptic syndromes in infancy, childhood and adolescence. 4th ed. London: John Libby Eurotext; 2005. p. 125\u2013148.","edition":"4"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1739606"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.3017"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202479"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4113"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199708283370901"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.65.1.35"},{"issue":"47","key":"e_1_3_4_53_1","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997","volume":"46","author":"Centers for Disease Control and Prevention (CDC)","year":"1997","unstructured":"Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep. 1997;46(47):1061\u20131066.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13195"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13407"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03495.x"},{"key":"e_1_3_4_57_1","volume-title":"Proceedings of the American Epilepsy Society","author":"Sullivan J","year":"2020","unstructured":"Sullivan J, Lagae L, Cross J, et al. Fenfluramine (FINTEPLA) in Dravet syndrome: results of a third randomized, placebo-controlled clinical trial (study 3). Proceedings of the American Epilepsy Society; Virtual. 2020."},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2022.05.006"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108212"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.09.021"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu11071596"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511.17.3.180"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.06.040"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02952.x"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008741"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2021.10.024"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.10.006"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14658"},{"key":"e_1_3_4_69_1","unstructured":"British National Formulary For ChIldren (BNFC) online. Fenfluramine - medicinal forms [cited 2023 Nov 28]. Available from: https:\/\/bnfc.nice.org.uk\/drugs\/fenfluramine\/medicinal-forms\/"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2024.2313548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:49:43Z","timestamp":1727207383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2024.2313548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,3]]}},"alternative-id":["10.1080\/14737175.2024.2313548"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2024.2313548","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}